Cholesterol lowering with statins: how WOSCOPS confounded the skeptics - PubMed

Cholesterol lowering with statins: how WOSCOPS confounded the skeptics

J Shepherd. Atheroscler Suppl. 2007 Aug.

Abstract

The appearance of statins was key to our understanding of the pathologic effects of hypercholesterolemia. Before statins were available, physicians did not know whether cholesterol lowering improved cardiovascular health. Pioneering studies such as the Framingham Study and MR FIT identified high blood cholesterol as a risk factor for cardiovascular disease. However, because total cholesterol (TC) < or =300 mg/dL was common physicians were not convinced that this was abnormal. Cholesterol reduction by cholestyramine, nicotinic acid, and fibrates reduced the risk of coronary artery disease, but these treatments did not improve survival and quality of life. In 1987, the first statin arrived. This class of agents lowered cholesterol effectively with minimal side effects. Guidelines started to recognize the importance of cholesterol reduction. There followed a series of endpoint studies that emphatically demonstrated that statins improved cardiovascular outcomes. The WOSCOPS trial showed in a large cohort of men with TC >250 mg/dL and no prior MI that pravastatin dramatically reduced MI incidence, cardiovascular and total mortality, and revascularizations versus placebo over 5 years. WOSCOPS revealed for the first time that statin was effective for primary prevention. The benefits appeared early and persisted even after treatment ended. Statins also changed our perceptions with surprising ancillary effects.

Similar articles

• Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin.

  Nakamura H; MEGA Study Group. Nakamura H, et al. Atheroscler Suppl. 2007 Aug;8(2):13-7. doi: 10.1016/j.atherosclerosissup.2007.02.003. Epub 2007 Jun 22. Atheroscler Suppl. 2007. PMID: 17586102 Clinical Trial.

• [Statins in primary prevention of coronary heart disease].

  Paulweber B. Paulweber B. Wien Med Wochenschr. 1999;149(5-6):129-38. Wien Med Wochenschr. 1999. PMID: 10408004 Review. German.

• Expected versus observed survival in 3 large population studies with HMG-CoA reductase inhibitors.

  Naslafkih A, Sestier F. Naslafkih A, et al. J Insur Med. 2000;32(3):155-62. J Insur Med. 2000. PMID: 15912915 Review.

• Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

  Cziraky MJ, Watson KE, Talbert RL. Cziraky MJ, et al. J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. J Manag Care Pharm. 2008. PMID: 19891279 Review.

Cited by

• Statins for the primary prevention of cardiovascular disease.

  Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Taylor F, et al. Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004816. doi: 10.1002/14651858.CD004816.pub5. Cochrane Database Syst Rev. 2013. PMID: 23440795 Free PMC article. Review.

• The rise of cholesterol testing: how much is unnecessary.

  Doll H, Shine B, Kay J, James T, Glasziou P. Doll H, et al. Br J Gen Pract. 2011 Feb;61(583):e81-8. doi: 10.3399/bjgp11X556245. Br J Gen Pract. 2011. PMID: 21276328 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Medical

  • MedlinePlus Health Information